MARKET

OTLKW

OTLKW

OUTLOOK THRAPTCS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.1735
+0.0134
+8.37%
Closed 16:00 12/03 EST
OPEN
0.1735
PREV CLOSE
0.1601
HIGH
0.1735
LOW
0.1735
VOLUME
2.05K
TURNOVER
--
52 WEEK HIGH
0.3489
52 WEEK LOW
0.0208
MARKET CAP
--
P/E (TTM)
-0.1260
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA (bevacizumab-vikg)
GlobeNewswire · 10/13 13:05
Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital
MONMOUTH JUNCTION, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence Kenyon
GlobeNewswire · 10/07 12:05
Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration
MONMOUTH JUNCTION, N.J., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) is a late clinical-stage biopharmaceutical company developing the first FDA-approved ophthalmic formulation of bevacizumab-vikg (LYTENAVA™) for use in retinal indications (known as ONS-5010). Outlook
GlobeNewswire · 09/30 13:05
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OTLKW. Analyze the recent business situations of OUTLOOK THRAPTCS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.41%
Pharmaceuticals & Medical Research
+0.49%
Key Executives
Chairman/Executive Director
Ralph Thurman
Chairman/Executive Director
Randy Thurman
President/Chief Executive Officer/Chief Financial Officer/Treasurer/Secretary/Director
Lawrence Kenyon
Chief Operating Officer
Terry Dagnon
Other
Jeff Evanson
Director
Gerd Auffarth
Director
Julian Gangolli
Director
Andong Huang
Independent Director
Yezan Haddadin
Independent Director
Kurt Hilzinger
Independent Director
Faisal Sukhtian
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OTLKW
Outlook Therapeutics, Inc., formerly Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company's other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Outlook Therapeutics Inc stock information, including NASDAQ:OTLKW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLKW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OTLKW stock methods without spending real money on the virtual paper trading platform.